AI Article Synopsis
- The case study investigates the effectiveness and safety of a Janus kinase (JAK) inhibitor for treating generalized eosinophilic pustular folliculitis (EPF) in a 16-year-old patient who did not respond to traditional treatments.
- The patient was initially treated with oral tofacitinib, resulting in significant symptom relief, but a relapse occurred when the dosage was reduced.
- A switch to the more selective JAK1 inhibitor upadacitinib led to complete recovery, suggesting that JAK inhibitors could be a viable option for EPF patients resistant to standard therapies.
Article Abstract
Aim: This case study aims to report the efficacy and safety of a Janus kinase (JAK) inhibitor in the treatment of generalized eosinophilic pustular folliculitis (EPF).
Methods: We present a case of a 16-year-old Chinese patient who had been suffering from EPF for two years and had shown no response to both topical and systemic glucocorticoids. The patient was subsequently treated with oral tofacitinib at a dosage of 5mg daily.
Results: Significant remission of eruption and pruritus was observed in the patient upon treatment with tofacitinib. However, a relapse occurred upon dose reduction. Subsequent switch to the highly selective JAK1 inhibitor upadacitinib resulted in complete recovery, with the patient achieving a symptom-free status after six months.
Conclusions: JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546634.2024.2331785 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!